RxDoctor Payments Data

Holly Cholvin, APRN

Psychiatric/Mental Health · St Petersburg, FLNPI 1619265006

Payments from drug & device makers

$301in general payments, 2019–2025

Across 13 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$87
  • AbbVie$81
  • Sage Therapeutics, LLC$28
  • Alkermes, Inc.$27
  • Johnson & Johnson$25
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$301 in reported general payments places this provider in the 30th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$2,022
Medicare patients
18
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate35$305,486
Austedo XrDeutetrabenazine19$112,052
RexultiBrexpiprazole49$76,558
VraylarCariprazine Hcl35$58,357
TrintellixVortioxetine Hydrobromide29$23,037
Aripiprazole167$22,781
Lurasidone Hcl59$18,485
VyvanseLisdexamfetamine Dimesylate41$17,001
BelsomraSuvorexant38$16,416
Duloxetine Hcl280$9,690
Quetiapine Fumarate335$9,087
Buspirone Hcl282$7,447
Quetiapine Fumarate ErQuetiapine Fumarate13$6,873
Chlorpromazine Hcl13$6,327
Hydroxyzine Hcl184$6,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$87$305,48635 claims
AbbVieVraylar$81$58,35735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →